Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elena Mironova
Institution:
The University of Texas at San Antonio Health Science Center
Observed institution:
The University of Texas at San Antonio Health Science Center
ORCID:
0000-0002-2579-5319
Observed ORCID:
0000-0002-2579-5319
OpenAlex ID:
A5077036034
Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors
2024
·
Elena Mironova
, Sebastian Molinas
, et al.
·
Cancers
·
5
PDF
Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
·
Clinical Cancer Research
·
3
Abstract 7040: The B7-H3 targeting antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) is potently effective against a broad panel of pediatric solid tumor xenograft models: A study from the Pediatric Preclinical In Vivo Testing (PIVOT) Consortium
2025
·
Haiying Tang
, Edward Favours
, et al.
·
Cancer Research
·
1
ENaC phosphorylation facilitates ankyrin-3 interaction critical for renal sodium balance
2026
·
Tarek Mohamed Abd El-Aziz
, Antonio G Soares
, et al.
·
PNAS Nexus
Supplementary Figure S2 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S5 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S8 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S11 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S4 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Data from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S4 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S2 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S6 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S3 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Figure S3 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Supplementary Table S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors
2026
·
Edward Favours
, Haiying Tang
, et al.
Show more works
View as search
Works count:
30
Citation count:
9
H-index:
2
I10-index:
Year
Topic
Type